Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 15/20 | 0.62 |
| ▸ | HTR2C | P28335 | 9/20 | 0.54 |
| ▸ | DRD2 | P14416 | 7/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.54 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4710618 | 0.92 | HTR2A (0.59) | HTR2AHTR2CDRD2KCNH2TLR9 | |
| SCHEMBL5425794 | 0.88 | HTR2A (0.56) | HTR2AHTR2CDRD2KCNH2 | |
| SCHEMBL5434438 | 0.86 | HTR2A (0.62) | HTR2AHTR2CDRD2KCNH2TLR9 | |
| SCHEMBL4522438 | 0.86 | HTR2A (0.65) | HTR2AHTR2CDRD2KCNH2TLR9 | |
| Hydrochloric Acid SCHEMBL5414035 | 0.85 | HTR2A (0.64) | HTR2AHTR2CDRD2KCNH2TLR9 | |
| SCHEMBL5424647 | 0.84 | HTR2A (0.62) | HTR2AHTR2CDRD2KCNH2TLR9 | |
| SCHEMBL5417422 | 0.84 | HTR2A (0.56) | HTR2AHTR2CDRD2KCNH2TLR9 | |
| SCHEMBL5417469 | 0.83 | HTR2A (0.53) | HTR2AHTR2CDRD2KCNH2TLR9 | |
| SCHEMBL5420550 | 0.82 | HTR2A (0.52) | HTR2AHTR2CDRD2KCNH2 | |
| SCHEMBL5425941 | 0.82 | HTR2A (0.55) | HTR2AHTR2CDRD2KCNH2TLR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197603-A1 | Substituted indole ligands for the orl-1 receptor | GLAXOSMITHKLINE S.P.A. (IT) | 2007-08-23 | — | — | US | claimed |
| WO-2008000818-A1 | FLUORINATED INDOLEAMIDES USEFUL AS LIGANDS OF THE ORL-1 RECEPTOR | BRANE DISCOVERY S.R.L. (IT) | 2008-01-03 | — | — | WO | disclosed |
| EP-1873150-A1 | Fluorinated indoleamides useful as ligands of the ORL-1 receptor | NIKEM RESEARCH S.R.L. (IT) | 2008-01-02 | — | — | EP | disclosed |
| US-20070197603-A1 | Substituted indole ligands for the orl-1 receptor | GLAXOSMITHKLINE S.P.A. (IT) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197603-A1 | Substituted indole ligands for the orl-1 receptor | OGFRL1, OPRL1, ORMDL3 | HTR2A 147/4885HTR2C 192/4885DRD2 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.